#Canada #Montreal #Thryv Therapeutics #SGK1 inhibitors #Cardiovascular Diseases

Thryv Therapeutics Set to Engage Investors in 2025 Conferences

Thryv Therapeutics Inc., a clinical-stage biotechnology company, is gearing up to present its cutting-edge research at a series of significant healthcare investor conferences this fall. This event marks a pivotal moment for the Montreal-based company as it showcases breakthroughs in treatments for inherited cardiac arrhythmias and associated cardiovascular conditions.

Events Schedule

Thryv Therapeutics has confirmed its participation at multiple important conferences during November and December of 2025, with discussions centering on novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors. These innovative therapies have shown promise in addressing various cardiometabolic diseases, including Long QT Syndrome, atrial fibrillation, and heart failure. Here’s the scheduled lineup of events:

1. Wells Fargo Virtual Private Biopharma Symposium 2025:
- Format: Fireside chat and one-on-one investor meetings.
- Date: November 5, 2025.
- Location: Virtual.

2. Stifel Healthcare Conference 2025:
- Format: Presentation and one-on-one investor meetings.
- Date: November 13, 2025, from 2:30 PM to 3:15 PM EST.
- Location: Lotte New York Palace Hotel, New York, NY.

3. Jefferies Global Healthcare Conference 2025:
- Format: Investor meetings.
- Dates: November 17 – 21, 2025.
- Location: London, UK.

4. RBC Healthcare Private Company Conference 2025:
- Format: Fireside chat and one-on-one investor meetings.
- Date: December 11, 2025.
- Location: Virtual.

Company Focus

As part of its commitment to innovation in the field of precision cardiovascular medicine, Thryv Therapeutics aims to provide stakeholders with comprehensive updates on the progress of its SGK1 inhibitor pipeline and clinical programs. These inhibitors are being explored for their potential to transform the treatment landscape for patients suffering from genetic channelopathies and other cardiometabolic disorders.

Thryv’s approach leverages the high specificity of its SGK1 inhibitors, which could revolutionize how these complex conditions are managed. By targeting underlying mechanisms responsible for cardiac issues, Thryv hopes to enhance the quality of life for affected individuals significantly.

The team's engagement with investors is crucial in generating support for ongoing research efforts and bringing these therapies closer to market launch. Thryv encourages interested parties to arrange meetings during these conferences to discuss their strategies and future outlook related to novel treatments in cardiovascular health.

About Thryv Therapeutics

Founded in Montreal, Quebec, Thryv Therapeutics is dedicated to pioneering solutions for serious health conditions by combining biochemical innovation with clinical development. With a focus on precision medicine, the company is leading a charge to introduce effective treatments that address genetic disorders and improve cardiovascular health outcomes. To find out more about Thryv and its groundbreaking work, visit www.thryvtrx.com.

Thryv Therapeutics looks forward to sharing its vision and developments with the healthcare investment community at these prestigious events.

For further details or to schedule a meeting with Thryv Therapeutics during the conferences, please reach out via their contact email.